Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early bone biomarker response to teriparatide in postmenopausal osteopenia/osteoporosis
2006-004110-40Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of teriparatide in osteoporosis and osteopenia, sponsored by Novartis. Primary endpoints: Early bone formation and resorption biomarker response profiles (weeks 1–4) and Description of early bone formation biomarker response to teriparatide reference treatment. Started Sep 2006; status: completed.
02
Drugs
teriparatide
03
Conditions
osteoporosisosteopenia
Beyond the preview
Go deeper on 2006-004110-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004110-40.